118 related articles for article (PubMed ID: 36081648)
1. What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment.
Laurenti L; Gaidano G; Mauro FR; Molica S; Pasqualetti P; Scarfò L; Ghia P
Hemasphere; 2022 Sep; 6(9):e771. PubMed ID: 36081648
[TBL] [Abstract][Full Text] [Related]
2. Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
Sportoletti P; Laurenti L; Chiarenza A; Gaidano G; Albi E; Mauro FR; Trentin L; Vallisa D; Pane F; Cuneo A; Albano F; Zamprogna G; Coscia M; Gozzetti A; Reda G; Caira M; Finsinger P; Gualberti G; Iannella E; Malgieri S; Molica S
Hematol Oncol; 2024 Jan; 42(1):e3216. PubMed ID: 37772620
[TBL] [Abstract][Full Text] [Related]
3. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment.
Ravelo A; Myers K; Brumble R; Bussberg C; Koffman B; Manzoor BS; L Biondo JM; Mansfield C
Future Oncol; 2024 May; ():1-12. PubMed ID: 38861284
[TBL] [Abstract][Full Text] [Related]
4. Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study.
Boqué C; Abad MR; Agustín MJ; García-Goñi M; Moreno C; Gabás-Rivera C; Granados E; Castro-Gómez A; Pardo C; Lizán L
J Geriatr Oncol; 2020 Jan; 11(1):24-30. PubMed ID: 30954406
[TBL] [Abstract][Full Text] [Related]
5. Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis.
Landfeldt E; Eriksson J; Ireland S; Musingarimi P; Jackson C; Tweats E; Gaudig M
Leuk Res; 2016 Jan; 40():17-23. PubMed ID: 26654707
[TBL] [Abstract][Full Text] [Related]
6. Hematologists' Preferences for First-line Therapy Characteristics for Multiple Myeloma in Japan: Attribute Rating and Discrete Choice Experiment.
Bolt T; Mahlich J; Nakamura Y; Nakayama M
Clin Ther; 2018 Feb; 40(2):296-308.e2. PubMed ID: 29358004
[TBL] [Abstract][Full Text] [Related]
7. Patients' priorities in selecting chronic lymphocytic leukemia treatments.
Mansfield C; Masaquel A; Sutphin J; Weiss E; Gutierrez M; Wilson J; Boeri M; Li J; Reyes C
Blood Adv; 2017 Nov; 1(24):2176-2185. PubMed ID: 29296865
[TBL] [Abstract][Full Text] [Related]
8. Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects.
Le H; Ryan K; Wahlstrom SK; Maculaitis MC; Will O; Mulvihill E; LeBlanc TW
Patient Prefer Adherence; 2021; 15():99-110. PubMed ID: 33519195
[TBL] [Abstract][Full Text] [Related]
9. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
Fifer S; Rose J; Hamrosi KK; Swain D
BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
[TBL] [Abstract][Full Text] [Related]
10. Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.
Omori Y; Enatsu S; Cai Z; Ishiguro H
Breast Cancer; 2019 Sep; 26(5):652-662. PubMed ID: 30949915
[TBL] [Abstract][Full Text] [Related]
11. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.
Mühlbacher AC; Nübling M
Eur J Health Econ; 2011 Jun; 12(3):193-203. PubMed ID: 20107856
[TBL] [Abstract][Full Text] [Related]
12. Patient preferences and predicted relative uptake for targeted therapies in metastatic colorectal cancer: a discrete choice experiment.
Wong XY; Lim AQJ; Shen Q; Chia JWK; Chew MH; Tan WS; Wee HL
Curr Med Res Opin; 2020 Oct; 36(10):1677-1686. PubMed ID: 32609014
[TBL] [Abstract][Full Text] [Related]
13. Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
González JM; Doan J; Gebben DJ; Boeri M; Fishman M
Pharmacoeconomics; 2018 Aug; 36(8):973-986. PubMed ID: 29869777
[TBL] [Abstract][Full Text] [Related]
14. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
[TBL] [Abstract][Full Text] [Related]
15. Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis.
Alcusky M; Lee S; Lau G; Chiu GR; Hadker N; Deshpande A; Fleming S; Vance N; Fakharzadeh S
Dermatol Ther (Heidelb); 2017 Dec; 7(4):463-483. PubMed ID: 29052800
[TBL] [Abstract][Full Text] [Related]
16. What do Australian patients with inflammatory arthritis value in treatment? A discrete choice experiment.
Ho KA; Acar M; Puig A; Hutas G; Fifer S
Clin Rheumatol; 2020 Apr; 39(4):1077-1089. PubMed ID: 31858340
[TBL] [Abstract][Full Text] [Related]
17. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK.
Gelhorn HL; Stringer SM; Brooks A; Thompson C; Monz BU; Boye KS; Hach T; Lund SS; Palencia R
Diabetes Obes Metab; 2013 Sep; 15(9):802-9. PubMed ID: 23464623
[TBL] [Abstract][Full Text] [Related]
18. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment.
Augustovski F; Beratarrechea A; Irazola V; Rubinstein F; Tesolin P; Gonzalez J; Lencina V; Scolnik M; Waimann C; Navarta D; Citera G; Soriano ER
Value Health; 2013; 16(2):385-93. PubMed ID: 23538191
[TBL] [Abstract][Full Text] [Related]
19. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA
Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681
[TBL] [Abstract][Full Text] [Related]
20. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
